Low expression of RECQL is associated with poor prognosis in Chinese breast cancer patients

BMC Cancer

Table 1 Association between RECQL mRNA Expression and Clinicopathologic Characteristics (N = 774)

Characteristic	No.	RECQL mRNA expression				P
		Low		High
		No.	%	No.	%
Total	774	387	50.0	387	50.0
Age
≤ 50 yr	331	168	43.4	163	42.1	0.72
> 50 yr	443	219	56.6	224	57.9
Tumor size
≤ 2 cm	298	142	36.7	156	40.3	0.30
> 2 cm	476	245	63.3	231	59.7
Tumor grade
I	186	85	22.7	101	26.6	0.041
II	443	215	57.5	228	60.2
III	124	74	19.8	50	13.2
Unknown	21	13		8
Lymph node status
Negative	510	239	65.5	271	73.0	0.026
Positive	226	126	34.5	100	27.0
Unknown	38	22		16
ER status
Negative	223	124	32.1	99	25.6	0.047
Positive	549	262	67.9	287	74.4
Unknown	2	1		1
PR status
Negative	302	160	42.0	142	37.1	0.16
Positive	462	221	58.0	241	62.9
Unknown	10	6		4
HER2 status
Negative	556	254	66.0	302	78.2	< 0.001
Positive	215	131	34.0	84	21.8
Unknown	3	2		1
Ki-67
High	445	233	62.3	212	55.9	0.08
Low	308	141	37.7	167	44.1
Unknown	21	13		8
Subtype
Luminal A	173	76	19.8	97	25.1	0.003
Luminal B(HER2-)	268	119	30.1	149	38.6
Luminal B(HER2+)	123	78	20.3	45	11.7
HER2+	92	53	13.8	39	10.1
TN	114	58	15.1	56	14.5
Unknown	4	3		1
Adjuvant Therapy
C	157	83	21.4	74	19.1	0.011
E	281	121	31.3	160	41.3
C + E	245	127	32.8	118	30.5
No therapy	91	56	14.5	35	9.0
Trastuzumab use
No	739	372	96.1	367	94.8	0.39
Yes	35	15	3.9	20	5.2
Surgery type
BCS	294	137	37.4	157	42.1	0.20
Mastectomy	445	229	62.6	216	57.9
Unknown	35	21		14

Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; TN, triple negative; C, chemotherapy; E, endocrinotherapy; C + E, chemotherapy and endocrinotherapy; BCS, breast-conserving surgery
Comments: luminal A: ER+ or PR ≥ 20%, HER2-, Ki-67 < 14%; luminal B (HER2-): ER+ and HER2-, Ki-67 ≥ 14% or PR−/< 20%, luminal B (HER2+): ER+ and HER2+; HER2(+): ER- and PR-, HER2+; TN: ER- and PR-, HER2-

ISSN: 1471-2407